# Kedar Kirtane

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kedar-kirtane/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,580 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 16 |
| i10-index | 31 |
| Last Known Institution | Moffitt Cancer Center |
| OpenAlex ID | https://openalex.org/A5035287097 |
| ORCID iD | 0000-0003-1302-9577 |
| Works | 185 |

## Researcher papers

- [Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead](https://scholariq.org/papers/adoptive-cellular-therapy-in-solid-tumor-malignancies-review-of-the-literature/)
- [Racial and ethnic disparities in hematologic malignancies](https://scholariq.org/papers/racial-and-ethnic-disparities-in-hematologic-malignancies/)
- [Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma](https://scholariq.org/papers/recent-advances-and-future-directions-in-clinical-management-of-head-and-neck/)
- [T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study](https://scholariq.org/papers/t-cell-responses-to-individualized-neoantigen-therapy-mrna-4157-v940-alone-or-in/)
- [Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline](https://scholariq.org/papers/immunotherapy-and-biomarker-testing-in-recurrent-and-metastatic-head-and-neck/)
- [Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial](https://scholariq.org/papers/pembrolizumab-and-cabozantinib-in-recurrent-metastatic-head-and-neck-squamous/)
- [Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal](https://scholariq.org/papers/transplant-associated-thrombotic-microangiopathy-is-a-multifactorial-disease/)
- [Patient-reported outcomes in acute myeloid leukemia: Where are we now?](https://scholariq.org/papers/patient-reported-outcomes-in-acute-myeloid-leukemia-where-are-we-now/)
- [Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study](https://scholariq.org/papers/concurrent-cetuximab-and-nivolumab-as-a-second-line-or-beyond-treatment-of/)
- [Change in Patients’ Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma](https://scholariq.org/papers/change-in-patients-perceived-cognition-following-chimeric-antigen-receptor-t/)
- [Cutaneous Reactions to Iron Infusions: A Case Report and Clinical Review](https://scholariq.org/papers/cutaneous-reactions-to-iron-infusions-a-case-report-and-clinical-review/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Diagnosis and Treatment](https://scholariq.org/topics/cancer-diagnosis-and-treatment/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

## Researcher university

- [Moffitt Cancer Center](https://scholariq.org/institutions/moffitt-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.